BioPharma APAC

BioPharma Pharma Research

Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor

NMS-293 is a next generation, orally available, brain-penetrant PARP1 selective inhibitor NMS-293 is currently studied in Phase I as monotherapy for the...

September 27, 2022 | News

Sciwind Biosciences and SynerK Enter into Research Partnership

The partnership combines Sciwind's expertise in disease biology and clinical development capabilities with SynerK's proprietary conjugate-based siRNA deliv...

September 27, 2022 | News

AAHRPP Accredits Five More Research Organizations, Including First in Japan

At its September meeting, AAHRPP's Council on Accreditation awarded full accreditation to: Adventist Health Glendale, Glendale, California, a hospi...

September 26, 2022 | News

SCG Cell Therapy To Establish Cell Therapy Pilot cGMP Manufacturing Facility And R&D Centre In Singapore

With the support of the Singapore Economic Development Board (EDB), the hub comprises a pilot manufacturing facility and an R&D centre. SCG expect...

September 21, 2022 | News

CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte®

CorLiCyte® is in development for the treatment of a number of serious conditions, with a first target indication of treating diabetic foot ulcer (...

September 19, 2022 | News

United Imaging Announces Clinical System Installations at Huntsman Cancer Institute at the University of Utah

United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that The Center for Quantitative Cancer Imaging ...

September 16, 2022 | News

Merck announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients

First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential...

September 14, 2022 | News

Indica Labs announces collaboration with The Industrial Centre for Artificial Intelligence Research in Digital Diagnostics (iCAIRD)

Indica Labs, an industry leader in quantitative digital pathology and image management solutions, and The Industrial Centre for Artificial Intelligence Res...

September 07, 2022 | News

Breast Cancer AI Company FathomX Raises SGD$ 2.24 million in Pre-series A Funding

Through this funding, the company will be able to harness the full potential of its digital AI solution to read medical images including mammograms. The fu...

September 02, 2022 | News

EpiEndo Commences LPS Challenge Trial for Lead Candidate EP395

EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chro...

September 01, 2022 | News

Sanyou ,KangaBio to accelerate antibody drug development and innovation

KangaBio, as a rising star biotechnology company, is committed to developing innovative prodrugs and providing innovative medicine to address unmet clinica...

August 29, 2022 | News

Sonde Health Inks Multi-Year Partnership with Koye Pharmaceuticals

Sonde Health, a leading enterprise vocal biomarker company, has signed a multi-year agreement with Koye Pharmaceuticals, a specialty pharma organizati...

August 25, 2022 | News

CSIRO opens 'missing link' lab to developing Australian vaccine pipeline

CSIRO, Australia’s national science agency, has opened a new $23.1 million national lab in Melbourne that will bolster the nation’s ability to ...

August 11, 2022 | News

Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply

U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the JYNNEOS vaccine to allow healthcare providers to use the vaccine by i...

August 10, 2022 | News

Stay Connected